



amfAR BRIEFINGS

# Accelerating an HIV Prevention Revolution: A Roadmap

## Speaker Biographies

March 9, 2011



### **Susan J. Blumenthal, M.D., M.P.A., Moderator**

*Senior Policy and Medical Advisor  
amfAR, The Foundation for AIDS Research  
Former Assistant Surgeon General of the United States  
Former U.S. Deputy Assistant Secretary for Women's Health*

Rear Admiral Susan J. Blumenthal, M.D., M.P.A. (ret.) provides strategic direction and medical leadership in amfAR's Public Policy Office in Washington D.C. She is also a Clinical Professor at Georgetown and Tufts Schools of Medicine. For more than 20 years, Dr. Blumenthal served as a leading U.S. government health expert and spokesperson in positions including Assistant Surgeon General of the United States, the first-ever Deputy Assistant Secretary for Women's Health, Senior Global and e-Health Advisor in the U.S. Department of Health and Human Services, Chief of the Behavioral Medicine and Basic Prevention Research Branch at the National Institute of Mental Health, Chair of the Health and Behavior Coordinating Committee at the National Institutes of Health, and as a White House Advisor on health issues. Dr. Blumenthal has been a pioneer in bringing major public health issues including women's health, HIV/AIDS, mental illness, health information technology, and disease and violence prevention to increased public and scientific attention. She was a leader in the 1980s in exposing the inequities in women's health and in the 1990s was the top doctor in the Federal government to stimulate and coordinate new initiatives to move women's health issues to the forefront of our nation's healthcare agenda. Her work in the government has included a focus on HIV/AIDS since the beginning of the epidemic in the early 1980s. Dr. Blumenthal is the Public Health Editor of the *Huffington Post*. She also served as the health columnist for *US News and World Report* and as Medical Director and Host for an award-winning television series on health. She has received numerous awards including honorary doctorates and has been decorated with the highest medals of the U.S. Public Health Service for her significant contributions to improving health in the U.S. and internationally. Dr. Blumenthal was named the 2009 Health Leader of the Year by the Commissioned Officers Association and as a 2010 Rock Star of Science by the Geoffrey Beene Foundation.



### **Chris Collins, M.P.P., Discussant**

*Vice President and Director of Public Policy  
amfAR, The Foundation for AIDS Research*

Chris Collins is Vice President and Director of Public Policy at amfAR, The Foundation for AIDS Research. Collins has spent more than 18 years in HIV/AIDS policy and advocacy. Before joining amfAR, he was a consultant on policy and communications for numerous domestic and global health organizations. He is the author of *Improving Outcomes: Blueprint for a National AIDS Plan for the United States*, published by the Open Society Institute in 2007, and he helped organize the movement for development of a National HIV/AIDS Strategy for the U.S. As a consultant with the Bill & Melinda Gates Foundation, Collins coordinated the work of the Global HIV Prevention Working Group. He also oversaw production of the series of *Missing the Target* reports on international AIDS service scale-up produced by the International Treatment Preparedness Coalition (ITPC). Collins is a co-founder of the AIDS Vaccine Advocacy Coalition (AVAC), served as its Executive Director for two years, and remains on its board. As Appropriations Associate for Rep. Nancy Pelosi (now Minority Leader) in the late 1990s, Collins developed the first Congressional legislation designed to provide incentives for the development and delivery of vaccines against AIDS, malaria, and TB. Collins is the author of dozens of publications on HIV/AIDS policy. He holds a Master's Degree in Public Policy from the Kennedy School of Government at Harvard University.



**Emily Bass**  
*Program Director*  
*AVAC: Global Advocacy for HIV Prevention*

Ms. Bass joined AVAC in 2005 and has been Program Director since 2008, working with colleagues to develop advocacy strategies and programs focused on accelerating ethical clinical trials of and eventual access to new HIV prevention strategies including PrEP, microbicides, male circumcision and vaccines. As Program Director, she has led the design and inauguration of the HIV Prevention Research Advocacy Fellowship program, the Women's HIV Prevention Tracking Project and national-level civil society coalitions focused on ARV-based prevention in Kenya and Uganda. Ms. Bass's experience also includes more than a decade of work as an HIV/AIDS science writer and advocate with a focus on issues related to women, HIV, and sexual and reproductive health. Her writing has appeared in *Ms.*, *Out*, *Salon*, *POZ*, the *amfAR*

*Treatment Insider*, *HIV Plus* and *The Lancet Infectious Diseases*. She has spent nearly a decade following the response to HIV/AIDS in Uganda and was the recipient of a 2004 Fulbright grant to support reporting on the rollout of the country's national AIDS treatment program.



**Willard Cates, Jr., M.D., M.P.H.**  
*President, Research*  
*FHI*

Ward Cates is President, Research at FHI in Research Triangle Park, NC. He is also an Adjunct Professor of Epidemiology at the University of North Carolina-Chapel Hill Gillings School of Global Public Health and a Clinical Professor in UNC's Departments of Medicine and Obstetrics/Gynecology. Before joining FHI seventeen years ago, Dr. Cates was at CDC for two decades, where he directed the STD/HIV prevention efforts for half that time and helped lead CDC's reproductive health research activities for the other half. Dr. Cates received his undergraduate degree in history from Yale University; a master's degree in history from King's College, Cambridge University;

and a combined M.D.-M.P.H. degree from Yale School of Medicine; and completed his residency training in Internal Medicine at the University of Virginia Hospital. Dr. Cates is board-certified in preventive medicine. He is a member of the Institute of Medicine, National Academy of Sciences, the American College of Preventive Medicine, and past President of the Society for Epidemiologic Research. He has authored or co-authored more than 450 scientific publications. Dr. Cates is co-author of *Contraceptive Technology* and a past co-editor of *Sexually Transmitted Diseases*, 2<sup>nd</sup> edition.



**Grant Colfax, M.D.**  
*Director, HIV Prevention and Research*  
*San Francisco Department of Public Health*

Grant Colfax, M.D., is the Director of HIV Prevention and Research at the San Francisco Department of Public Health. The HIV Prevention Section oversees multiple HIV prevention efforts in San Francisco, with the goal of ending new HIV infections and ensuring that all HIV-infected persons are offered care and treatment. The HIV Prevention Section emphasizes effective, sustainable programs that are cost-efficient and accountable for decreasing HIV incidence and improving health equity. Dr. Colfax's office oversees San Francisco's publicly funded HIV testing and counseling programs, linkage and engagement in care for persons at risk and infected with HIV, syringe access programs, and substance abuse treatment for those at risk for HIV acquisition

and transmission. Under Dr. Colfax's direction, the section also works to inform policies, laws, and other structural factors that influence HIV prevention and treatment, emphasizing the need to address an individual's overall health as part of HIV prevention efforts. Dr. Colfax's NIH- and CDC-funded HIV prevention research includes epidemiologic assessments of populations at high-risk for HIV; analyses of community viral load; implementation studies to assess the population-level impact of innovative HIV prevention interventions; and clinical trials to reduce substance use. Dr. Colfax has published multiple papers and chapters on HIV prevention in peer-reviewed journals and books. He also sees patients at the San Francisco General Hospital HIV clinic, the Positive Health Program.



**Paul De Lay, M.D.**  
*Deputy Executive Director  
UNAIDS*

Paul De Lay joined UNAIDS in February 2003 and was appointed the Deputy Executive Director, Program, in June 2009. Since 1988, Dr. De Lay has been engaged in strategic planning, implementing, and monitoring national and international AIDS programs. During his previous role as Director of UNAIDS's Department for Evidence, Monitoring and Policy (EMP), Dr. De Lay provided leadership in promoting a comprehensive, evidence-informed, and adequately resourced response to the HIV epidemic. This included providing strategic information and policy guidance, monitoring programmatic coverage and behavioral trends, building country capacity, and evaluating the effectiveness of the response at the country, regional, and global levels. The Department also coordinates the annual reporting to the UN Secretary-General on progress toward achieving the UN General Assembly Special Session Declaration of Commitment. As Deputy Executive Director, Dr. De Lay works to implement the new vision for UNAIDS, which includes the priorities of the new Executive Director and will reflect the findings and recommendations of the Second Independent Evaluation and other current analyses of roles, responsibilities, and functions within the joint program. He is a medical doctor who practiced medicine for 15 years with training and clinical experience in family practice, infectious and tropical diseases, epidemiology, preventive medicine, and public health. He previously worked with the Global Program on AIDS at the World Health Organization and served as Chief of the HIV/AIDS Division at USAID. Dr. De Lay received a medical degree from the University of California, is board-certified in preventive medicine and public health, and holds a Diploma of Tropical Medicine and Hygiene from London School of Hygiene and Tropical Medicine.



**Don Des Jarlais, Ph.D.**  
*Director of Research, Rothschild Chemical Dependency Institute  
Beth Israel Medical Center  
Professor, Department of Epidemiology and Public Health  
Albert Einstein College of Medicine*

Dr. Des Jarlais began his research on AIDS in 1982 and is recognized as a world leader in research on the epidemiology of HIV transmission among injection drug users (IDUs). He is also a pioneer in the evaluation of a variety of harm reduction interventions, particularly syringe exchange programs, and was instrumental in the development and expansion of syringe exchange programs in New York City during the 1980s. Dr. Des Jarlais has published more than 350 articles on these topics. In 1989, Dr. Des Jarlais was jointly appointed by the President and Congress to serve as a Commissioner on the U.S. National Commission on AIDS, a role he played until 1993. He has testified on many occasions before Congressional, state and city legislative committees on HIV prevention and syringe exchange. Since 1994, Dr. Des Jarlais' research group at Beth Israel Medical Center has conducted annual surveys of syringe exchange programs in the United States. He currently serves as a consultant to various institutions, including the Centers for Disease Control and Prevention (CDC), the National Institute on Drug Abuse, the National Academy of Sciences, and the World Health Organization. Dr. Des Jarlais is currently working on research studies in 20 different countries. He is a Core Member of the Reference Group to the United Nations on HIV and Injecting Drug Use and a member of the Scientific Advisory Board for the President's Emergency Program for AIDS Relief (PEPFAR).



**Carl Dieffenbach, Ph.D.**  
*Director, Division of AIDS  
National Institute of Allergy and Infectious Diseases, NIH*

Dr. Carl W. Dieffenbach received his bachelor's degree in biochemistry from the University of Maryland in 1976 and his Ph.D. in biophysics from Johns Hopkins University in 1983. He completed his Postdoctoral Fellowship with the Uniformed Services University of the Health Sciences (USUHS), Department of Pathology, in 1984, and was then promoted to the rank of Assistant Professor. While at USUHS he ran a highly productive research program, pioneering uses of polymerase chain



reaction in understanding mechanisms of cytokine gene expression and cloned the cellular receptor for the murine coronavirus, Mouse Hepatitis Virus. In 1992, he joined the National Institutes of Allergy and Infectious Diseases' (NIAID), Division of AIDS (DAIDS) as the Chief of the preclinical therapeutics group. Upon his initial NIAID appointment, Dr. Dieffenbach spearheaded important research initiatives that accelerated the progress of basic research on HIV pathogenesis and directly resulted in new clinical studies of novel AIDS therapies. In 1996, he was promoted to director of the Basic Sciences Program within DAIDS, where he remained until being selected as the Division Director in 2008. Additionally, Dr. Dieffenbach has continued to serve as an Associate Professor of Pathology, F. Edward Hebert School of Medicine, and as a faculty member and director for the HIV/AIDS course in the NIH graduate school, FAES. He is also a co-author of the Cold Spring Harbor Laboratory Manuals *PCR Primer* 1<sup>st</sup> and 2<sup>nd</sup> editions, which were published in 1995 and 2003 respectively. As the DAIDS director, Dr. Dieffenbach has oversight of a global HIV/AIDS research portfolio of more than \$1 billion and a staff of more than 140 federal employees.




**Kevin Fenton, M.D., Ph.D., F.F.P.H.**

*Director, National Center for HIV/AIDS, Viral Hepatitis, STD & TB Prevention  
Centers for Disease Control and Prevention*

Kevin Fenton, M.D., Ph.D. is the Director of the National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP) at the U.S. Centers for Disease Control and Prevention (CDC). Prior to the CDC, Dr. Fenton was the Director of the HIV and Sexually Transmitted Infections Department in the United Kingdom's Health Protection Agency (HPA). During Dr. Fenton's leadership at NCHHSTP, CDC released revised recommendations on routine testing of HIV to increase the number of persons knowing their status, and provided novel national HIV incidence estimates that will enable us to better focus our prevention efforts and measure our success. CDC also worked to engage, mobilize, and partner with at-risk communities to promote health equity and reduce health disparities through national initiatives and

funding, and recently launched the first national HIV/AIDS public health education program in twenty years. In 2007, NCHHSTP's programs were recognized as being among the four percent of federal programs to receive the highest rating of "effective" by the U.S. Office of Management and Budget. Dr. Fenton has served in a number of international, academic, and community leadership positions, and has received numerous awards. He has published more than 200 peer-reviewed articles, book chapters and reports on HIV and STD epidemiology, and sexual health policy, with a special emphasis on racial and ethnic health disparities.



**Barney S. Graham, M.D., Ph.D.**

*Chief, Clinical Trials Core; Chief, Viral Pathogenesis Lab, Vaccine Research Center  
National Institute of Allergy and Infectious Diseases, NIH*

Dr. Barney Graham is an immunologist, virologist, and clinical trials physician whose primary interests are viral pathogenesis, immunity, and vaccine development. His work is focused on HIV, respiratory syncytial virus (RSV), and emerging viral diseases. After graduating from Rice University, he obtained his M.D. from the University of Kansas, School of Medicine in 1979. He then completed his residency in internal medicine, a fellowship in infectious diseases, and a Ph.D. in microbiology and immunology at Vanderbilt University School of Medicine, where he rose to the rank of Professor of Medicine with a joint appointment in the Department of Microbiology & Immunology. In 2000 Dr. Graham became one of the founding investigators for the NIAID Vaccine

Research Center at NIH, where he currently serves as the Chief of the Viral Pathogenesis Laboratory and Clinical Trials Core. His laboratory investigates immunopathology, the basic mechanisms by which T cells affect viral clearance, and how T-cell function can be modulated by vaccination. Vaccine development for RSV and understanding how RSV influences and evades adaptive immunity are projects of particular interest. The clinical trials unit directed by Dr. Graham evaluates experimental viral vaccines in phase I studies with a primary emphasis on candidate vaccines for HIV, biodefense, and emerging infectious diseases. Dr. Graham is a member of the American Society for Clinical Investigation and the American Association of Physicians, and a Fellow in the Infectious Disease Society of America and the American Academy of Microbiology. Dr. Graham has authored more than 200 scientific publications and is a member of the editorial board for the *Journal of Biological Chemistry*.



**Robert Grant, M.D., M.P.H.**

*Senior Investigator, Gladstone Institute of Virology and Immunology,  
Associate Professor of Medicine, University of California, San Francisco  
Protocol Chair, iPrEx Clinical Study*

Dr. Robert Grant is a Senior Investigator at the Gladstone Institute of Virology and Immunology and an Associate Professor of Medicine at the University of California, San Francisco. He has more than 26 years of experience with AIDS clinical care and research, which includes four years in leading epidemiological studies in San Francisco and Uganda, followed by a fellowship in molecular medicine, after which he established the Gladstone/UCSF Laboratory of Clinical Virology in 1997 and then the Gladstone Laboratory of Molecular Evolution in 2000. Dr. Grant is currently the protocol chair for the Pre-Exposure Prophylaxis (or PrEP) Initiative study, which involves use of antiviral

agents to block transmission of HIV-1 to highly exposed persons, combined with standard preventive care. This global clinical trial has sites in Peru, Ecuador, Brazil, the United States, South Africa, and Thailand—settings where HIV-1 continues to spread. Dr. Grant's laboratory is also leading research to understand the biological and social implications of PrEP, which may include immune responses due to viral antigen exposure during PrEP, low-level drug resistance, and alterations in HIV testing and disclosure in social networks. His laboratory is also studying HIV-1 superinfection (where persons already infected with HIV-1 might acquire additional strains of the virus). Understanding when superinfection occurs, and when it does not, could provide clues to protective immunity that would help guide future HIV vaccine development studies. Dr. Grant's team has also investigated the consequences of molecular evolution, including (1) the fitness of drug-resistant HIV-1 for replication, virulence, and transmission; (2) mechanisms of mutagenesis that underlie viral evolution; and (3) nonpathogenic simian immunodeficiency virus (SIV) infection in natural host species. The long-term goal of this research is to increase understanding of the viral and social characteristics that underlie patterns of epidemic spread of HIV-1 in human communities. Dr. Grant is a Betty Jean and Hiro Ogawa Endowed Investigator. He has served as a member of the U.S. FDA Antiviral Advisory Committee and has authored more than 95 publications.



**John T. McDevitt, Ph.D.**

*Brown-Wiess Professor of Chemistry and Bioengineering  
Rice University*

Dr. John T. McDevitt, the Brown-Wiess Professor of Chemistry and Bioengineering at Rice University in Houston, Texas, is a pioneer in the development of the Programmable Bio-Nano-Chip (PBNC). The McDevitt research group integrates nanometer-sized molecular sensors with microchip-based technology for diagnostic devices that rapidly analyze blood, saliva and other fluids to detect toxins, drugs, antibodies, metabolites, bacteria, blood products and more. PBNCs are currently the focus of concurrent clinical trials for HIV/AIDS, oral, ovarian and prostate cancers, cardiac disease, and drugs of abuse. Dr. McDevitt joined Rice in 2009 after two decades at the University of Texas at

Austin. At Rice, he and his collaborators continue to develop inexpensive, battery-powered devices that can replace time-consuming, expensive, lab-based tests. Easy-to-use PBNCs have immense potential to impact clinical medicine in developing countries, where traditional laboratory measurements are not practical, and in developed countries seeking to reduce healthcare costs. Dr. McDevitt's research has been supported by the National Institutes of Health, the Bill and Melinda Gates Foundation, the Welch Foundation, the Doris Duke Charitable Foundation, the National Science Foundation, the Office of Naval Research, CPRIT and others. His novel work has been featured in *Science*, *Business Week*, and *Popular Science*. A PBNC system used in pre-hospital settings to test saliva for signs of heart attacks was selected by *Popular Science* as the "Best of What's New" (2008) in the medical devices category. Dr. McDevitt's innovative work was also named one of the Science Coalition's Best Scientific Advances in 1998. Other notable honors include the Presidential Young Investigator Award and the Exxon Education Award. Dr. McDevitt has authored more than 150 patents and patent applications and published more than 160 peer-reviewed manuscripts. He received a bachelor of science in chemistry in 1982 from California Polytechnic State University, San Luis Obispo, California, where he was recently honored as the Distinguished Alumnus for the College of Science and Mathematics. In 1987, Dr. McDevitt earned a doctoral degree in chemistry from Stanford University and completed a postdoctoral fellowship at the University of North Carolina.



**Paul Meyer, J.D.**  
*Chairman and President*  
*Voxiva, Inc.*

Paul Meyer is Co-founder, Chairman, and President of Voxiva. Founded in 2001, Voxiva is a leading global provider of interactive mobile health information services. In 2011, Voxiva was named one of the World's 50 Most Innovative Companies by Fast Company. Voxiva solutions are used by leading public and private health organizations in 14 countries around the world for health prevention and wellness, patient monitoring and support, disease surveillance and data collection. In early 2010, Voxiva and its partners launched Text4baby, a free SMS information service for pregnant women and new moms that is the largest mobile health service in the United States. Before founding Voxiva, Paul co-founded IPKO, the leading Internet Service Provider and mobile phone operator in Kosovo. Previously he was a Senior Fellow at the Markle Foundation, Chief Operating Officer of Endeavor, and worked for the International Rescue Committee. From 1993 to 1995, Mr. Meyer served as one of President Clinton's White House speechwriters. He has a law degree from Yale Law School and studied politics at Oxford. Mr. Meyer was named a Young Global Leader by the World Economic Forum in Davos, a Henry Crown Fellow at the Aspen Institute, and a Term Member of the Council on Foreign Relations. MIT's *Technology Review* magazine named him a Technology Pioneer and as their 2003 Humanitarian of the Year.



**Robert H. Remien, Ph.D.**  
*Researcher, HIV Center for Clinical and Behavioral Studies, NYS Psychiatric Institute*  
*Professor of Clinical Psychology (in Psychiatry), College of Physicians and Surgeons,*  
*Columbia University*

Robert H. Remien, Ph.D., is Professor of Clinical Psychology (in Psychiatry) at Columbia University. He is also the Director of the HIV Center's Global Community Core, faculty mentor for HIV Center Postdoctoral Fellows, and a clinical supervisor to psychiatric residents in training. Recently, Dr. Remien served as Chair for the New York State Psychological Association's Task Force on AIDS. He is a member of the New York City's Department of Health Prevention Planning Group and senior faculty for the American Psychological Association's HIV training program for psychologists.

Dr. Remien's research is focused on mental health, sexual risk behavior, and adherence to treatment and care. He has developed and tested several behavioral interventions in these domains in both domestic and international settings. As a researcher in the HIV Center at the NYS Psychiatric Institute from its establishment, he has published numerous articles on psychopathology and psychological resilience, psychoimmunology, coping and adaptation to chronic illness among individuals, couples, and families, sexual and health behaviors, long-term survival with HIV/AIDS, and acute HIV infection. Dr. Remien has worked to facilitate numerous collaborations and partnerships among health departments, community-based organizations, and clinic sites on behalf of the HIV Center and its investigators.



**Zeda Rosenberg, Sc.D.**  
*CEO*  
*International Partnership for Microbicides*

Dr. Zeda Rosenberg is founder and CEO of the International Partnership for Microbicides, a non-profit product development partnership established to prevent HIV transmission by accelerating the development and availability of safe and effective microbicides for women in developing countries. Previously, Dr. Rosenberg was Scientific Director for the HIV Prevention Trials Network at Family Health International and Senior Scientist at the U.S. National Institute of Allergy and Infectious Diseases, where she focused on HIV prevention trials, microbicides, and tuberculosis research. She received her bachelor's degree in biology and mathematics from Rutgers

University, as well as her master's degree in epidemiology and doctoral degree in microbiology from the Harvard School of Public Health.



**Ron Stall, Ph.D., M.P.H.**

*Professor and Chair, Department of Behavioral and Community Health Sciences  
Graduate School of Public Health, University of Pittsburgh*

Ron Stall is Professor and Chair of the Department of Behavioral and Community Health Sciences in the Graduate School of Public Health at the University of Pittsburgh. Dr. Stall began work on the AIDS epidemic in 1984 on the AIDS Behavioral Research Project, one of the first longitudinal studies of AIDS risk-taking behaviors in the world. Since that time he has published over 135 peer reviewed scientific papers on many different aspects of the AIDS epidemic, including methodological research, research on determinants of risk-taking behaviors and HIV seroconversion, life course issues important to AIDS risk-taking behavior, behavioral intervention research, studies on care-seeking behavior for HIV infection, and a portfolio of research on global AIDS issues. Dr. Stall is particularly proud of his record of collaborative research conducted with AIDS community-based organizations, which include a broad range of organizations within the United States and abroad. He is the 1999 recipient of the Chuck Frutchey Board of Directors Award from STOP AIDS/San Francisco, is listed as one of the most highly cited behavioral science researchers in the world in the ISI Most Highly Cited website, received the 2005 CDC/ATSDR Honor Award for Public Health Epidemiology and Laboratory Research, and was inducted into Delta Omega (a public health honor society) in 2006. His current research and teaching portfolio includes Co-Directorship of a Certificate Program in LGBT Health, and as the Principal Investigator or Co-PI on several NIH grants focusing on gay men's health issues.



**amfAR, The Foundation for AIDS Research**  
Public Policy Office  
1150 17<sup>th</sup> St NW, Suite 406, Washington, DC 20036-4622  
t: 202.331.8600 • f: 202.331.8606 • [www.amfar.org](http://www.amfar.org)